Sign In
Buy CLDX
$33.41
+0.98 (+3.02%)
At Close: Jun 22, 2026
Celldex Therapeutics (CLDX) Reports Q4 Loss, Tops Revenue Estimates
09:11am, Monday, 26'th Feb 2024
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.76. This compares to loss of $0.56 per share a year ago.
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
07:01am, Monday, 26'th Feb 2024
- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - En
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
02:05pm, Saturday, 24'th Feb 2024
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups - - Sustained activity with rapid ons
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
04:01pm, Tuesday, 06'th Feb 2024
HAMPTON, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Ann
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
08:01am, Monday, 05'th Feb 2024
HAMPTON, N.J., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that an abstract describing 12 week results from the Company's Phase 2 clinical trial of barzo
MoneyShow's Best Investment Ideas For 2024: Part 3
10:45am, Monday, 29'th Jan 2024
MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth
MoneyShow's Best Investment Ideas For 2024: Part 2
05:30pm, Friday, 26'th Jan 2024
MoneyShow presents top investment ideas for 2024 from their contributors. This year's edition presents a broad mix of conservative income stocks, more speculative but potentially more rewarding growth
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
04:15pm, Monday, 27'th Nov 2023
HAMPTON, N.J., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the 6th Annual Evercore ISI HealthCONx
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
01:08pm, Friday, 17'th Nov 2023
The article embarks on a transformative journey through the biotech frontier, where the listed companies stand as titans reshaping healthcare norms. The first one's strategic collaboration with a mult
Why Celldex Therapeutics Blasted 13% Higher on Monday
06:47pm, Monday, 06'th Nov 2023
A leading pipeline drug did very well in phase 2 clinical testing. Barzolvolimab met its primary endpoint, and was generally well tolerated.
Celldex Therapeutics shares surge as lead asset shows promise in two skin conditions
08:15am, Monday, 06'th Nov 2023
Celldex Therapeutics CLDX, +8.20% shares jumped more than 30% premarket on Monday after the company released positive clinical trial results for its lead asset in both chronic hives and an inflammator
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
08:31am, Monday, 25'th Sep 2023
HAMPTON, N.J., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Cantor Global Healthcare Conferenc
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates
06:57pm, Tuesday, 08'th Aug 2023
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.65 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.58 per share a year ago.
Celldex Therapeutics to Present at Jefferies Healthcare Conference
08:01am, Friday, 02'nd Jun 2023
HAMPTON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on
Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates
07:44pm, Thursday, 04'th May 2023
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.49 per share a year ago.
